Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 15/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14902382 | 0.93 | MME (0.50) | MMEATMCTSSCTSK | |
| SCHEMBL18874742 | 0.90 | MME (0.53) | MMEATMCTSSCTSKSCN9A | |
| SCHEMBL18626426 | 0.89 | MME (0.59) | MME | |
| SCHEMBL20306289 | 0.86 | MME (0.60) | MMEATMCTSSCTSKMMP2 | |
| SCHEMBL18874681 | 0.82 | MMEL1 (0.49) | MMESCN9A | |
| SCHEMBL20099586 | 0.82 | MME (0.55) | MMEATMCTSSCTSKSCN9A | |
| SCHEMBL11969730 | 0.82 | MME (0.54) | MMEATMCTSSCTSKSCN9A | |
| SCHEMBL11970064 | 0.82 | MME (0.54) | MMEATMCTSSCTSKSCN9A | |
| SCHEMBL18411073 | 0.82 | MME (0.54) | MMEATMCTSSCTSKSCN9A | |
| SCHEMBL20099600 | 0.81 | MME (0.58) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744104-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190262297-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20170327459-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9688616-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-27 | — | — | US | disclosed |
| US-9682052-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170015619-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015619-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ATM 4839/4885CTSS 113/4885 |
| US-10744104-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ATM 4869/4885CTSS 86/4885 |
| US-20190262297-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ATM 4869/4885CTSS 86/4885 |
| US-20170327459-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ATM 4839/4885CTSS 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.